Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Nanobiotix ( (NBTX) ) is now available.
Nanobiotix, a company involved in the biotechnology industry, has disclosed transactions involving the allocation of free shares to key executives. On June 27, 2025, several transactions were made outside trading platforms, involving the allocation of free shares to individuals in managerial roles, including the CEO and other executives. This move, disclosed on July 2, 2025, is part of the company’s strategy to align management incentives with company performance, potentially impacting stakeholder perceptions and market positioning.
The most recent analyst rating on (NBTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The overall score for Nanobiotix is primarily impacted by severe financial instability and negative valuation metrics, which significantly weigh down its investment appeal. Although some technical indicators suggest potential short-term stability, they are not sufficient to offset the broader financial concerns.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Average Trading Volume: 10,233
Technical Sentiment Signal: Hold
Current Market Cap: $227.8M
For detailed information about NBTX stock, go to TipRanks’ Stock Analysis page.